1.Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
Marco PETRILLO ; Massimo ZUCCHETTI ; Stefano CIANCI ; Lavinia MOROSI ; Carlo RONSINI ; Andrea COLOMBO ; Maurizio D'INCALCI ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2019;30(4):e59-
OBJECTIVE: Evidences from animal models seem to suggest that minimally invasive surgery may enhance cisplatin diffusion when the drug is administered in the context of post-operative hyperthermic intraperitoneal chemotherapy (HIPEC). The present study evaluates the cisplatin pharmacokinetic profile in a prospective series of women with platinum sensitive recurrent epithelial ovarian cancer treated with open secondary cytoreductive surgery (O-SCS) or minimally-invasive secondary cytoreductive surgery (MI-SCS). METHODS: Cisplatin levels were assessed at 0, 20, 40, 60, and 120 minutes in: 1) blood samples, 2) peritoneal perfusate, and 3) peritoneal biopsies at the end of HIPEC. Median Cmax has been used to identify women with high and low drug levels. Progression-free survival (PFS) was calculated as the time elapsed between SCS+HIPEC and secondary recurrence or last follow-up visit. RESULTS: Nine (45.0%) women received MI-SCS, and 11 (55.0%) O-SCS. At 60 minutes, median cisplatin Cmax in peritoneal tissue was higher in patients treated with MI-SCS compared to O-SCS (Cmax=8.262 µg/mL vs. Cmax=4.057 µg/mL). Furthermore, median cisplatin plasma Cmax was higher in patients treated with MI-SCS compared to O-SCS (Cmax=0.511 vs. Cmax=0.254 µg/mL; p-value=0.012) at 120 minutes. With a median follow-up time of 24 months, women with higher cisplatin peritoneal Cmax showed a longer PFS compared to women with low cisplatin peritoneal levels (2-years PFS=70% vs. 35%; p-value=0.054). CONCLUSIONS: We demonstrate for the first time that minimally invasive route enhances cisplatin peritoneal tissue uptake during HIPEC, further evaluations are needed to confirm the correlation between peritoneal cisplatin levels after HIPEC and survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01539785
Biopsy
;
Cisplatin
;
Cytoreduction Surgical Procedures
;
Diffusion
;
Disease-Free Survival
;
Drug Therapy
;
Endoscopy
;
Female
;
Follow-Up Studies
;
Humans
;
Injections, Intraperitoneal
;
Minimally Invasive Surgical Procedures
;
Models, Animal
;
Ovarian Neoplasms
;
Pharmacokinetics
;
Plasma
;
Platinum
;
Prospective Studies
;
Recurrence
2.ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
Giulia AMADIO ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2020;31(1):6-
1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.CONCLUSIONS: Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.]]>
Aged
;
Bevacizumab
;
Case-Control Studies
;
Comorbidity
;
Creatinine
;
Diagnosis
;
Drug Therapy
;
Female
;
Glomerular Filtration Rate
;
Humans
;
Logistic Models
;
Ovarian Neoplasms
3.ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
Giulia AMADIO ; Claudia MARCHETTI ; Emanuele Rocco VILLANI ; Domenico FUSCO ; Francesca STOLLAGLI ; Carolina BOTTONI ; Mariagrazia DISTEFANO ; Giuseppe COLLOCA ; Giovanni SCAMBIA ; Anna FAGOTTI
Journal of Gynecologic Oncology 2020;31(1):e6-
Objective:
Bevacizumab maintenance following platinum-based chemotherapy is an effective treatment for epithelial ovarian cancer (EOC), both in primary and recurrent disease. Our aim was to identify criteria to select elderly patients who can safely benefit from bevacizumab addition.
Methods:
This is a case-control study on patients with primary or recurrent EOC who received platinum-based chemotherapy plus bevacizumab, between January 2015 and December 2016. Patient characteristics, treatment details and adverse events were reviewed and analyzed in 2 settings: younger (<65 years, group 1) and elderly (≥65 years, group 2). A binary logistic model was applied to correlate clinical variables and severe (grade ≥3) toxicity risk.
Results:
Overall, 283 patients with EOC were included, with 72 (25.4%) older patients compared with 211 (74.6%) younger women. Bevacizumab had been administered to 234 patients (82.7%) as first-line treatment and in 49 (17.3%) with recurrent disease. At diagnosis, elderly patients presented with at least one comorbidity and were taking at least 1 medication in 84.7% and 80.6% of the cases respectively, compared with correspondingly 47.4% and 37.4% in group 1 (p<0.001). Nonetheless, the occurrence of serious (grade ≥3) adverse events did not increase among the older group. Creatinine serum levels >1.1 g/dL, estimated glomerular filtration rate (eGFR) ≤60 mL/min, ≥3 comorbidities were independently associated with a higher severe toxicity.
Conclusions
Elderly patients with EOC can safely be treated with bevacizumab; factors other than age, as higher creatinine serum levels, eGFR and number of comorbidities should be considered to better estimate bevacizumab-related toxicity risk.